Evaluate Group was established in 1996 by Dr. Jonathan de Pass, a former medical practitioner and a top-ranked pharmaceutical industry analyst. Dr. de Pass realized that the health care market needed a better way to get forward-looking market intelligence and the latest news and analysis in order to make sound business decisions for investment and growth.
Over the years, EvaluatePharma has become the industry leader in consensus forecast analysis of the biotech and pharma sector. In 2011 EvaluateClinical Trials was launched to provide deeper insight into global R&D intelligence and analysis, and in 2012 EvaluateMedTech set a new standard in integrated analysis and consensus forecasts to 2022 of the medical device and diagnostic industry.
Dr. de Pass’ vision has been, and continues to be, to make Evaluate the market intelligence and analysis service of choice in the life sciences industry, providing massive productivity gains and must-have data and analysis to its users. This is achieved through our client focus and engagement, and our continual investment in our services to support our clients’ business objectives. At its utmost, Evaluate’s vision is to help speed innovation, value and sustainability to the healthcare industry and the patients it serves, by providing trusted intelligence our clients can act on.